Answers are grounded in this paper and cite their sources.
OBJECTIVE: Existing mepolizumab trials have excluded patients with severe asthma with an eosinophilic phenotype (SAEP) from India. This study (NCT04276233) investigated the safety and effectiveness of mepolizumab in Indian adults with SAEP. METHODS: ), peak expiratory flow (PEF), and Asthma Control Questionnaire (ACQ-5) scores. CONCLUSIONS: Mepolizumab was well tolerated in Indian adults with SAEP and improved asthma control and health-related quality of life.
No takes yet. Share an insight, caveat, or question.
Meshram et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: